Reginald men Apollo Facewash for skin brightening and hydration

A Clinical study to Evaluate the effectiveness of Reginald men Apollo Facewash for skin brightening and hydration - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2025/09/094362

Enrollment

Registered

2025-09-08

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: Reginald men Apollo Facewash: Test Product: Reginald men Apollo Facewash Dose: Gently use the Reginald men Apollo Facewash twice a day for 4 weeks . Rinse well. Route of A

Eligibility

Inclusion criteria

Inclusion criteria: 1) Gender: Male and Female with age 18-45 (80:20) 2) Subjects with mild blemishes and dull skin. 3) Subjects willing to give written informed consent 4) Women of child bearing potential must have a negative urine pregnancy test prior to study entry. 5) Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events. 6) Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study.

Exclusion criteria

Exclusion criteria: 1.Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, in the last 5 years, or any other confounding skin condition. 2.Have open sores or open lesions in the treatment area(s). 3.Have any condition that, in the opinion of the investigator, would confound the safety and/or efficacy assessments of the product. 4.Have participated in any interventional clinical trial in the previous 90 days. 5.Have a known sensitivity to any of the constituents of the test product including sensitivities. 6. Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including corticosteroids. 7. Have not skin?related?issues

Design outcomes

Primary

Measure	Time frame
1. Change in skin brightness 2. Change in Skin Softness 3. Change in Skin hydration 4. Change in TEWL 5. Change in Skin discoloration 6. Change in Skin PigmentationTimepoint: At T0mins , T30mins, Day14 and T28days	—

Secondary

Measure	Time frame
SGATimepoint: At 28days	—

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results